Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07613047 · ClinicalTrials.gov registry record · NA
Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix
A NA study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT07613047 is a NA study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 70 participants.
The verdict
NCT07613047, a NA study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
This investigator-initiated study will compare ADM and resorbable cross-linked collagen membrane barriers for guided bone regeneration at atrophic lateral ridge augmentation sites.
Interventions
- PROCEDURE Guided Bone Regeneration with ADM (AlloDerm) as a barrier
- PROCEDURE Guided Bone Regeneration with Resorbable Crosslinked Collagen Matrix (Mem-Lok) as a barrier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-10 |
| Est. Completion | 2028-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07613047
The ClinicalTrials.gov registry entry for NCT07613047 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guided Bone Regeneration with ADM (AlloDerm) as a barrier is the first listed.
NCT07613047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07613047 about?
NCT07613047 is a clinical study titled "Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix". This investigator-initiated study will compare ADM and resorbable cross-linked collagen membrane barriers for guided bone regeneration at atrophic lateral ridge augmentation sites.
What is the current status of trial NCT07613047?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2026-10. Estimated completion is 2028-10.
What interventions are being tested in trial NCT07613047?
The interventions under investigation include: Guided Bone Regeneration with ADM (AlloDerm) as a barrier (PROCEDURE), Guided Bone Regeneration with Resorbable Crosslinked Collagen Matrix (Mem-Lok) as a barrier (PROCEDURE).
Who is sponsoring clinical trial NCT07613047?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.